Beyond Zero Risk: Rethinking Quality Management in Outsourced Biopharmaceutical Manufacturing

For decades, the biopharmaceutical industry has operated under a tacit assumption: when it comes to quality and compliance, more is always better. More procedures. More documentation. More bureaucracy. More caution. That zero-risk mentality, while understandable in an industry where patient safety is paramount, has quietly become one of the sector’s most significant barriers to effective outsourced manufacturing—and we see its consequences regularly in our consulting work.

The good news is that a shift is underway. Regulators, sponsors, and experienced CDMOs are increasingly recognizing that pragmatic, risk-based quality management isn’t a compromise—it’s a more sophisticated and ultimately more proactive approach than the compliance-theater model it replaces.

The Cost of Perfectionism

One of the most common patterns we observe in outsourced operations is what we call “empire building.” Rather than designing quality systems that are lean, efficient, and genuinely protective, organizations sometimes create complexity that sounds good from a podium but whose systems are so intricate that only their architects can navigate them. This provides a kind of job security and a perception of control, but it delivers very little return on investment and can actively impede manufacturing agility.

The zero-risk mentality also shows up in regulatory filings. Young companies, in particular, are understandably anxious to demonstrate rigor to agencies and often over-describe their manufacturing processes. What feels like thoroughness in the filing stage can later become an operational straitjacket. Locking in specific materials, equipment configurations, or procedural details at early development phases constrains the flexibility needed as a process scales toward commercial manufacturing, often without getting alignment from their CDMO. The big lesson, hard-learned by many, is not to be overly descriptive in filings—details that seem like due diligence at Phase 1 can require costly amendments at Phase 3.

Organizational dynamics in outsourced models exacerbate this tendency. With sponsors frequently operating as lean virtual companies—sometimes as few as 4 people managing a network of CDMOs and contract laboratories—the knowledge gap between sponsors and manufacturers can be significant. Bench scientists accustomed to the flexibility of a laboratory environment sometimes struggle to adapt to the discipline of commercial manufacturing, treating the manufacturing floor as an extension of their lab and making constant mid-process changes. The documentation burden this creates—and the deviations and investigations that follow—impose real costs on CDMOs that are already operating on tight margins, as well as delays in deliverables expected by the sponsor.

A Better Framework: Risk-Based Quality

The alternative is not less diligence—it is more strategically allocated diligence. A risk-based approach asks three fundamental questions for every quality activity: What is the return on doing this now? What is the patient and regulatory risk at this stage of the process? And what is the worst outcome if it is not done at this time? That framework focuses resources on the issues that genuinely matter to product quality and patient safety, while resisting the pull toward perfecting things that have minimal impact.

Practically, this means distinguishing between quality activities that must remain tightly controlled in-house and those that can be efficiently outsourced to specialists. Core QA functions—batch release, deviation management, change control—should remain internal to the manufacturing site. These activities require access to real-time operational information and site-specific institutional knowledge that cannot be effectively managed remotely. Document control, from SOPs to batch records, similarly demands on-site, easily controlled availability.

At the same time, certain QA activities are well-suited to outsourcing. Supplier audits, for instance, can be effectively and efficiently handled by qualified consultants or third parties. For QC testing, the calculus is more nuanced. Routine in-process control testing—endotoxin assays, identity tests, the analyses needed to progress a batch—should generally remain in-house for speed and control. Complex characterization and final release testing, however, can and often should be handled by specialist contract testing laboratories that have invested deeply in particular analytical capabilities.

The critical caveat when outsourcing any testing function is time. The moment you hand a sample to an external laboratory, you lose direct control of your timeline. Without robust service-level agreements that specify turnaround commitments and escalation pathways, you may find yourself waiting on results while a batch sits in limbo. That risk must be actively managed.

“A CDMO with excellent manufacturing execution and strong in-process control, paired with a carefully selected external testing partner, may ultimately serve your program better than a facility trying to do everything under one roof.”

Rethinking the One-Stop-Shop Model

The “one-stop-shop” CDMO model, which began evolving in the 2000s and 2010s, is undergoing a quiet reassessment. Comprehensive in-house QC capabilities were once a standard selling point—and for some programs, they remain the right choice. But the true cost of full-service QC is often understated. The visible return from testing services looks attractive; what it doesn’t capture is the ongoing cost of errors, rework, out-of-specification investigations, write-ups, and audits. These hidden costs, combined with the burden of maintaining and retaining specialized laboratory staff, are prompting CDMOs to reconsider where their investments are best deployed.

For sponsors, this evolving landscape means being more intentional about what you actually need from a CDMO versus what looks reassuring in a capabilities presentation. A CDMO with excellent manufacturing execution and strong in-process control, paired with a carefully selected external testing partner, may ultimately serve your program better than a facility trying to do everything under one roof.

The Regulatory Relationship

Perhaps no symptom of zero-risk thinking is more visible than the anxiety that surrounds FDA inspections. A Form 483—the FDA’s notice of inspectional observations—is widely treated as a harbinger of catastrophe. It should not be. The agency reviews operations across a broad spectrum of the industry, from leading-edge facilities to organizations still running on decades-old systems. Observations on a 483 represent the agency’s informed perspective on where a quality system can improve. Engaging with them constructively, with genuine corrective action rather than defensive minimization, is both the professionally appropriate response and a practical opportunity to modernize systems that may genuinely have become liabilities.

The same spirit should govern the broader sponsor-CDMO-agency relationship. Regulatory agencies are not adversaries to be managed; they share the fundamental goal of ensuring safe and effective products reach patients. Companies that engage early and transparently—bringing regulators into their development thinking rather than presenting them with finished filings—consistently fare better than those who treat regulatory strategy as damage control.

What the Industry’s Own Research Confirms

The tensions we observe in client engagements are documented at scale by industry research. Cytiva’s 2025 Global Biopharma Index—a biennial survey of 1,250 senior biopharma executives across 22 countries, published in October 2025—found that 40% of respondents believe cost-cutting is actively compromising product quality at their organizations, and 36% report that process changes are driven more by financial pressure than quality rationale. The overall industry resilience score fell to 5.96 out of 10 in 2025, down from 6.08 in 2023 and 6.60 in 2021—a trajectory that reflects the cumulative strain of short-term priorities overriding long-term operational discipline.

This data does not indict risk-based quality management—it indicts the absence of it. The organizations driving these metrics are not the ones making principled, quality-rational decisions about where to allocate resources. They are cutting costs without a framework, responding to financial pressure rather than quality rationale. That is precisely the failure mode a risk-based approach is designed to prevent. Bureaucratic compliance theater and undisciplined cost-cutting are two sides of the same coin: both substitute the appearance of rigor for its substance.

The regulatory response to that declining performance has been direct. FDA’s FY2024 quality report documented 989 drug inspections—a 27% year-over-year increase—with 561 Form 483s issued to drug program firms and over 62% of inspections targeting foreign manufacturing sites, the highest foreign-inspection share on record. In the first half of FY2025 alone, warning letters increased 73% compared to the same period in FY2024. And in June 2025, the FDA launched an internal AI system called ‘Elsa’ that analyzes 483 observation histories, adverse events, and CAPA records to prioritize high-risk facilities for inspection algorithmically. Quality systems that exist primarily on paper will increasingly find themselves at the top of that list.

The ISPE Global Pharmaceutical Innovation Survey adds a further dimension: 48% of respondents identified regulatory challenges as the most significant or significantly greater barrier to developing innovative manufacturing technology. The irony is that notable organizations that over-specify their regulatory filings and build bureaucratic quality systems around compliance theater find themselves less equipped, not more, to respond to the agency’s actual expectations for quality maturity and continuous improvement.

Raising the Bar on Human Factors

People ultimately execute quality systems—and that human dimension is too often an afterthought in quality design. Manufacturing is behaviorally driven. Operators must take steps, attach connections, follow sequences, and make judgment calls under time pressure. A quality system that ignores that reality, that piles procedures on top of procedures without asking whether they are operationally feasible, will fail not through any gap in documentation but through the accumulated weight of the unworkable.

The most effective quality cultures we have observed treat their manufacturing teams as partners in quality—training them to understand why procedures exist, not just how to follow them, and building feedback mechanisms that surface operational friction before it becomes a compliance problem.

The goal, ultimately, is not 100% on every dimension. The real objective is conformance to requirements, with genuine criticality placed where it belongs—on the things that protect patients and product integrity. That is a higher bar than it sounds. And it is a far more sophisticated ambition than simply doing more of everything.

Lisa Cozza and Scott Myers are principals at Tunnell Consulting, specializing in quality management, regulatory compliance, and outsourced manufacturing strategy for biopharmaceutical companies.